This Antibody-Mediated Rejection (AMR) - Epidemiology Forecast-2032 report delivers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Rejection trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The phenotype of AMR ranges from hyperacute rejection, acute AMR, and chronic AMR. AMR diagnosis depends on typical histological lesions, C4d staining, and serum DSA detection. C4d, a protein from the classical complement activation cascade that remains attached to the site of complement activation, is regarded as a diagnostic marker for AMR. The introduction of C4d as a marker of AMR aroused an ever-increasing interest in recognizing mechanisms of allograft rejection. AMR episodes occurring at different periods seem to be different clinical sub-entities. Early AMR is usually correlated with sensitization, pre-existing alloantibodies, and rapid graft dysfunction and is usually easy to be controlled; while late AMR is mostly correlated with withdrawal or reduction of immunosuppressants and noncompliance with immunosuppressive therapy, whereas late AMR has little response to antirejection strategies and thus correlate with poor graft outcomes.
The diagnosis of AMR - as defined by the modified Banff 97 and recently revised in the Banff 2019 classification - requires three cardinal features, including (a) functional evidence of allograft dysfunction, (b) morphological evidence of acute tissue injury, and evidence of Ab-dependent activation of the classical pathway of the complement system (i.e., C4d deposition in the peritubular capillaries), and detection of circulating DRSA. This report covers five major organ transplants where AMR is defined, namely Kidney, Lung, Liver, Heart, and Pancreas.
In the year 2021, the total cases of Antibody-Mediated Rejection were 5,102 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Antibody-Mediated Rejection epidemiology ,segmented as Transplant Incident cases and Total cases of Antibody-Mediated Rejection in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Antibody-Mediated Rejection (AMR) Understanding
The 's Antibody-Mediated Rejection market report gives a thorough understanding of Antibody-Mediated Rejection. Antibody‐mediated rejection (AMR) is a significant complication following organ transplantation that contributes to short‐ and long‐term injury in transplant recipients. Despite desensitization protocols, up to one‐third of highly sensitized recipients may develop acute AMR following transplantation. AMR is also of significant concern in non-sensitized individuals, as de novo DSAs can develop early or late after transplantation.The phenotype of AMR ranges from hyperacute rejection, acute AMR, and chronic AMR. AMR diagnosis depends on typical histological lesions, C4d staining, and serum DSA detection. C4d, a protein from the classical complement activation cascade that remains attached to the site of complement activation, is regarded as a diagnostic marker for AMR. The introduction of C4d as a marker of AMR aroused an ever-increasing interest in recognizing mechanisms of allograft rejection. AMR episodes occurring at different periods seem to be different clinical sub-entities. Early AMR is usually correlated with sensitization, pre-existing alloantibodies, and rapid graft dysfunction and is usually easy to be controlled; while late AMR is mostly correlated with withdrawal or reduction of immunosuppressants and noncompliance with immunosuppressive therapy, whereas late AMR has little response to antirejection strategies and thus correlate with poor graft outcomes.
The diagnosis of AMR - as defined by the modified Banff 97 and recently revised in the Banff 2019 classification - requires three cardinal features, including (a) functional evidence of allograft dysfunction, (b) morphological evidence of acute tissue injury, and evidence of Ab-dependent activation of the classical pathway of the complement system (i.e., C4d deposition in the peritubular capillaries), and detection of circulating DRSA. This report covers five major organ transplants where AMR is defined, namely Kidney, Lung, Liver, Heart, and Pancreas.
Antibody-Mediated Rejection (AMR) Epidemiology
The epidemiology section provides insights about the historical and current Antibody-Mediated Rejection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Antibody-Mediated Rejection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.In the year 2021, the total cases of Antibody-Mediated Rejection were 5,102 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Antibody-Mediated Rejection epidemiology ,segmented as Transplant Incident cases and Total cases of Antibody-Mediated Rejection in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Antibody-Mediated Rejection Epidemiology
The epidemiology segment also provides the Antibody-Mediated Rejection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.KOL-Views
To keep up with the current Antibody-Mediated Rejection patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Antibody-Mediated Rejection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.Scope of the Report
- The report covers the descriptive overview of Antibody-Mediated Rejection, explaining their causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Antibody-Mediated Rejection.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The disease epidemiology covered in the report provides historical as well as forecasted Antibody-Mediated Rejection epidemiology [segmented as Transplant incident cases (by organs) and Antibody-Mediated Rejection cases (by organ transplant)] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Antibody-Mediated Rejection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Antibody-Mediated Rejection.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Antibody-Mediated Rejection (AMR) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Antibody-Mediated Rejection Epidemiology Segmentation
Key Questions Answered
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Antibody-Mediated Rejection?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Antibody-Mediated Rejection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Antibody-Mediated Rejection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Antibody-Mediated Rejection?
- Out of all 7MM countries, which country would have the highest incident population of Antibody-Mediated Rejection during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Antibody-Mediated Rejection Disease market
- To understand the future market competition in the Antibody-Mediated Rejection Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Antibody-Mediated Rejection Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Antibody-Mediated Rejection Disease market
- To understand the future market competition in the Antibody-Mediated Rejection Disease market
Table of Contents
1. Key Insights2. Report Introduction5. Epidemiology and Market Methodology10. Unmet needs12. Publisher Capabilities13. Disclaimer14. About the Publisher
3. Antibody-Mediated Rejection (AMR) Market Overview at a Glance
4. Executive Summary of Antibody-Mediated Rejection (AMR)
6. Disease Background and Overview
7. Diagnosis and Differential diagnosis of Antibody-Mediated Rejection
8. Treatment of Antibody-mediated Rejection
9. Epidemiology and Patient Population
11. Appendix
List of Tables
List of Figures
